WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers. The... The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the body digests foreign, potentially...
- Mechanism
- Curator reviewed
WF 10 is a 1: 10 dilution of tetrachlorodecaoxide (TCDO) formulated for intravenous injection. It was developed by Oxo Chemie in Switzerland as an adjunctive therapy to combination antiretroviral and opportunistic infection prophylaxis regimens in AIDS patients. WF 10 specifically targets macrophages. WF10 potentially modulates disease-related up-regulation of immune responses both in vitro and in vivo. Thus immune response is influenced in a way that inappropriate inflammatory reactions are downregulated.
- Primary indication
- Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, cancer/tumors (unspecified), HIV infection, and inflammatory disorders (unspecified).Curator reviewed · 9 structured indications
- Formula / weight
- Cl4H2O11 · 319.821 g/mol (avg)
- Also known as
- TCDO · Tetrachlorodecaoxygen
- Code names
- WF 10
Resolves to
What you can answer from here — as of September 01, 2026
Which drugs share a target with Tetrachlorodecaoxide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account